Show Summary Details
Page of

Pulmonary amyloidosis 

Pulmonary amyloidosis
Pulmonary amyloidosis

S. J. Bourke

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 March 2021

Pulmonary amyloidosis is characterized by the deposition of monoclonal immunoglobulin light chain (AL) amyloid protein locally or diffusely in lung tissue. Local amyloid deposits in the airways, produced by B-cell clones within local tissues, may cause stridor, wheeze, cough, and haemoptysis. Diffuse alveolar deposition can occur as a complication of systemic amyloidosis. Local deposits of amyloid in the larynx, trachea, or bronchi may require treatment by endoscopic interventions, with mechanical debulking by forceps resection or laser therapy. Stenting may also be used to maintain airway patency. Radiotherapy has also been deployed successfully, and in certain circumstances may be a better option with less risk of bleeding or recurrence. Systemic AL amyloidosis may be treated by chemotherapy, while diffuse alveolar amyloidosis has a poor prognosis, particularly because it is associated with cardiac and renal amyloidosis.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.